Author:
Mecocci P.,Polidori M. C.,Cherubini A.,Senin U.
Reference173 articles.
1. Agnoli A, Fabbrini G, Fioravanti M, Martucci N. CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study. Eur. Neuropsychopharmacol. 2:31–35, 1992.
2. Amenta D, Ferrante F, Franch F, Amenta F. Effects of long-term Hydergine administration on lipofuscin accumulation in senescent rat brain. Gerontologist 34:250–256, 1988.
3. Andersen K, Launer LJ, Ott A, et al. Do nonsteroidal antiinflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam Study. Neurology, 45: 1441, 1995.
4. Augustinsson LE, Blennow K, Blomstrand C, et al. Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients. Dementia (in press).
5. Banfi S, Dorigotti L. Experimental behavioural studies with oxiracetam on different types of chronic cerebral impairment. Clin. Neuropharmacol. 7 (Suppl. 1):768–769, 1984.